{Reference Type}: Journal Article
{Title}: Diabetic Neuropathy: A Guide to Pain Management.
{Author}: Zhang EX;Yazdi C;Islam RK;Anwar AI;Alvares-Amado A;Townsend H;Allen KE;Plakotaris E;Hirsch JD;Rieger RG;Allampalli V;Hasoon J;Islam KN;Shekoohi S;Kaye AD;Robinson CL;
{Journal}: Curr Pain Headache Rep
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 5
{Factor}: 3.904
{DOI}: 10.1007/s11916-024-01293-9
{Abstract}: <B>OBJECTIVE: </B>Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.<BR><B>RESULTS: </B>Up to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients. Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.